Clinical Trials · NCT02359500

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

TerminatedPhase 1Octreotide (Prohibited)
Phase
Phase 1
Recruitment status
Terminated
Sponsor
Lale Kostakoglu
Enrollment
71
Start date
Dec 2014
Locations
1 site, United States
Primary endpoint
Change in size of lesion
View Octreotide compound reference